Medical options to fight mortality in end-stage renal disease: A review of the literature

Nephrology Dialysis Transplantation

Volumn 27, Issue 12, 2012, Pages 4298-4307

  Kramann, Rafael ^a   Floege, Jürgen ^a   Ketteler, Markus ^b   Marx, Nikolaus ^a   Brandenburg, Vincent M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b KLINIKUM COBURG   (Germany)

Author keywords

cardiorenal syndrome; cardiovascular mortality; end stage renal disease; mortality; treatment

Indexed keywords

ACETYLCYSTEINE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR; CALCIUM ACETATE; CALCIUM CARBONATE; CANDESARTAN; CARVEDILOL; COBALAMIN; CYANOCOBALAMIN; ERYTHROPOIETIN; EZETIMIBE PLUS SIMVASTATIN; FOLIC ACID; FOSINOPRIL; GROWTH HORMONE; HOMOCYSTEINE; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXINE; ROSUVASTATIN; SEVELAMER; TELMISARTAN; VALSARTAN;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; ENZYME INHIBITION; HEART INFARCTION; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL;

HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871191878     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs400     Document Type: Article

References (54)

1. Foley RN, Gilbertson DT, Murray T et al. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365: 1099-1107.
2. Wanner C, Krane V, Marz Wet al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
3. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
4. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
5. Cooper BA, Branley P, Bulfone L et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010; 363: 609-619.
6. Jamison RL, Hartigan P, Kaufman JS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-1170.
7. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
8. Zoungas S, McGrath BP, Branley P et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47: 1108-1116.
9. Takahashi A, Takase H, Toriyama Tet al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 2006; 21: 2507-2512.
10. Wrone EM, Hornberger JM, Zehnder JL et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426.
11. Suzuki H, Kanno Y, Sugahara S et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
12. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
13. Heinz J, Kropf S, Domrose U et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010; 121: 1432-1438.
14. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
15. Slama M, Susic D, Varagic J et al. Echocardiographic measurement of cardiac output in rats. Am J Physiol Heart Circ Physiol 2003; 284: H691-H697.
16. Pieper GM, Shah A, Harmann L et al. Speckle-tracking 2-dimensional strain echocardiography: a new noninvasive imaging tool to evaluate acute rejection in cardiac transplantation. J Heart Lung Transplant 2010; 29: 1039-1046.
17. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
18. Leitman M, Lysyansky P, Sidenko S et al. Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr 2004; 17: 1021-1029.
19. Smeets B, Kuppe C, Sicking EM et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1262-1274.
20. Kalantar-Zadeh K, Block G, Humphreys MH et al.Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
21. Zoccali C, Benedetto FA, Mallamaci F et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774.
22. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
23. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
24. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
25. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
26. Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001; 74: 130-136.
27. Boushey CJ, Beresford SA, Omenn GS et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
28. Collaboration HS. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-2022.
29. Dierkes J, Domrose U, Westphal S et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000; 102: 1964-1969.
30. Vianna AC, Mocelin AJ, Matsuo T et al. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 2007; 11: 210-216.
31. Tepel M, Echelmeyer M, Orie NN et al. Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int 2000; 58: 867-872.
32. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998; 53: 1748-1754.
33. Becker BN, Himmelfarb J, Henrich WL et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475-486.
34. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218.
35. Tepel M, van der Giet M, Statz M et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995.
36. Balk EM, Lichtenstein AH, Chung M et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19-30.
37. Geleijnse JM, Giltay EJ, Grobbee DE et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493-1499.
38. von Schacky C, Angerer P, Kothny W et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130: 554-562.
39. Kristensen SD, Iversen AM, Schmidt EB. n-3 polyunsaturated fatty acids and coronary thrombosis. Lipids 2001; 36(Suppl): S79-S82.
40. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003; 38: 343-352.
41. Christensen JH. n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability. Dan Med Bull 2003; 50: 347-367.
42. Svensson M, Schmidt EB, Jorgensen KA et al.N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006; 1: 780-786.
43. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
44. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
45. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439.
46. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
47. Guerin AP, London GM, Marchais SJ et al.Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
48. Cice G, Di Benedetto A, D'Isa S et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a doubleblind, placebo-controlled trial. J Am Coll Cardiol 2010; 56: 1701-1708.
49. Zannad F, Kessler M, Grunfeld JP et al. FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. Fundam Clin Pharmacol 2002; 16: 353-360.
50. Zoccali C, Benedetto FA, Mallamaci F et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol 2004; 15: 1029-1037.
51. Cice G, Ferrara L, Di Benedetto A et al. Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37: 407-411.
52. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
53. Green D, Roberts PR, New DI et al. Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis 2011; 57: 921-929.
54. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324.